Venous Stents Market: Rising Prevalence of Venous Disorders and Minimally Invasive Procedures Drive Growth
Venous Stents Market Estimation, Growth Drivers & Opportunities
The Venous Stents Market is expanding as the prevalence of venous disorders increases and healthcare systems increasingly adopt minimally invasive treatment procedures. According to Maximize Market Research, the market was valued at USD 1,250.74 million in 2023 and is expected to grow at a CAGR of 8.8% from 2024 to 2030, reaching nearly USD 2,257.20 million by 2030. Venous stents are used to maintain blood flow through narrowed or blocked veins and are increasingly applied in conditions such as deep vein thrombosis (DVT), post-thrombotic syndrome, and other venous obstructions. Growth is supported by the aging population, increasing prevalence of venous diseases, greater awareness of treatment options, and rising healthcare expenditure. The growing adoption of outpatient and day-care procedures is also improving demand for minimally invasive venous interventions. Technological improvements in stent materials, flexibility, radial strength, compression resistance, delivery systems, and biocompatibility are creating additional opportunities. The development of innovative stents and increasing emphasis on value-based healthcare are expected to provide further growth opportunities.
* Access Exclusive Industry Data: https://www.maximizemarketresearch.com/request-sample/231857/
U.S. Market Trends and Investment
The United States remains a major market for venous stents, supported by high healthcare expenditure, advanced vascular-care infrastructure, and a large patient population affected by chronic venous disease. In 2025, U.S. regulatory activity highlighted continued innovation in venous stent technology. The FDA approved the GORE VIABAHN FORTEGRA Venous Stent in December 2025 for symptomatic inferior vena cava obstruction, with or without combined iliofemoral obstruction, expanding treatment options for complex venous disease. The FDA also approved several 2025 supplements involving existing venous stent technologies, including Medtronic's Abre Venous Self-expanding Stent System and Philips' Duo Venous Stent System. These developments indicate continuing investment in device refinement, manufacturing processes, delivery systems, and clinical applications, supporting the broader U.S. venous stents market.
Deep Vein Thrombosis Segment Holds the Largest Market Share
Based on treatment, the Deep Vein Thrombosis (DVT) segment held the largest market share of approximately 45% in 2023, according to MMR. The segment is expected to maintain its leading position and grow at a CAGR of 8.8% during the forecast period. DVT can significantly restrict blood flow and may contribute to post-thrombotic syndrome, creating demand for effective interventions. Venous stenting provides a minimally invasive approach for restoring and maintaining venous blood flow in appropriately selected patients. Advancements in stent design, flexibility, radial strength, and delivery systems are improving treatment capabilities and supporting adoption.
Venous Stents Market Key Players
North America
1. Abbott(Chicago)
2. Becton, Dickinson and Company (New Jersy)
3. Cardinal Health (Dublin)
4. Cook Group Inc. (USA)
5. Boston Scientific Corporation (Massachusetts)
6. W.L Gore & Associates (USA)
7. Cordis (USA)
Europe
1. Medtronic (Ireland)
2. Koninklijke Philips N.V. (Netherlands)
3. OptiMedizinische Instrumente GmbH (Germany)
4. plus medica GmbH & Co. KG (Germany)
5. Jotech GmbH (Germany)
6. Plus Medica (Germany)
7. Stentys (France)
8. Translumina GmbH (Germany)
Asia Pacific
1. Meril Life Sciences Pvt Ltd (India)
2. MicroPort Scientific Corporation (China)
3. Terumo Corporation (Japan)
Competitive Analysis
MMR identifies Abbott, Becton, Dickinson and Company, Cardinal Health, Cook Group Inc., and Boston Scientific Corporation among the key players in the global market. The MMR report does not provide individual percentage shares for these companies; therefore, exact company market-share rankings cannot be stated reliably.
Abbott continues to strengthen its broader vascular-device portfolio through investment in technologies addressing complex vascular disease. Its acquisition of Cardiovascular Systems expanded its vascular treatment capabilities and complemented its existing imaging and stent portfolio.
Becton, Dickinson and Company (BD) markets the Venovo Venous Stent System, a purpose-built nitinol device for iliofemoral venous lesions. Its design combines radial strength, flexibility, compression resistance, and a tri-axial delivery system intended to support accurate deployment.
Cardinal Health announced in 2025 that it planned to invest at least $600 million annually in capital expenditures to support organic growth across its businesses. Its continued investment in technology-enabled healthcare capabilities and medical-product infrastructure can support its vascular-device activities.
Cook Group Inc. continued emphasizing product innovation and clinical evidence in 2025. Cook published real-world data comparing its Zilver PTX drug-eluting stent with Boston Scientific's Eluvia, demonstrating its continued focus on evidence-based vascular-device development.
Boston Scientific Corporation continues to invest heavily in medical-device innovation and vascular therapies. Its portfolio includes technologies for venous disease and thromboembolic conditions, while the company also maintains a strategic investment and acquisition program focused on innovative medical technologies.
Regional Analysis
USA: North America dominated the global Venous Stents Market with more than 40% share in 2023, according to MMR. The United States benefits from high healthcare expenditure, advanced hospitals and vascular centers, skilled specialists, favorable insurance coverage, and strong investment in medical-device research.
UK: The UK benefits from an established healthcare system, specialist vascular services, and growing awareness of minimally invasive treatment options. These factors support the adoption of advanced venous interventions.
Germany: Germany's developed healthcare infrastructure, advanced medical-device industry, and strong engineering capabilities support demand for innovative venous stent technologies.
France: France provides opportunities through its established healthcare system, specialist vascular care, and increasing emphasis on minimally invasive procedures.
Japan: Japan's aging population creates a substantial need for treatment of venous disorders. Advanced healthcare infrastructure and growing adoption of minimally invasive procedures support market development.
China: China represents an important long-term opportunity as healthcare infrastructure expands, disposable incomes increase, and awareness of advanced treatment options grows.
Related Reports:
Global Superficial Radiation Therapy System Market https://www.maximizemarketresearch.com/market-report/global-superficial-radiation-therapy-system-market/81456/
Global Image Guided Surgery Devices Market https://www.maximizemarketresearch.com/market-report/image-guided-surgery-devices-market/37264/
Global Cellulite Treatment Market https://www.maximizemarketresearch.com/market-report/cellulite-treatment-market/122922/
Conclusion
The Venous Stents Market is positioned for strong expansion as healthcare providers seek minimally invasive solutions for venous obstruction and DVT-related complications. The combination of an aging population, rising disease prevalence, improved diagnosis, advanced nitinol stent designs, better delivery systems, and increasing outpatient treatment is expected to remain central to market growth. The strongest opportunity lies in developing venous stents that provide greater flexibility, compression resistance, precise deployment, and durable vessel patency while supporting cost-effective care. Continued regulatory approvals and clinical evidence for dedicated venous technologies are likely to accelerate adoption and create new opportunities for manufacturers worldwide.
About Maximize Market Research
Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.
Contact Maximize Market Research
MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? sales@maximizemarketresearch.com
